{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:41:57Z","timestamp":1767847317634,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12954-019-0299-1","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T14:24:26Z","timestamp":1556547866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3045-5386","authenticated-orcid":false,"given":"Siyan","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phalkun","family":"Mun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pheak","family":"Chhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navy","family":"Chann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sovannary","family":"Tuot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitau","family":"Mburu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"issue":"9","key":"299_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/jvh.12123","volume":"20","author":"GS Cooke","year":"2013","unstructured":"Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the global burden of disease: a need to regroup. J Viral Hepat. 2013;20(9):600\u20131. \n                    https:\/\/doi.org\/10.1111\/jvh.12123\n                    \n                  .","journal-title":"J Viral Hepat"},{"issue":"4","key":"299_CR2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342. \n                    https:\/\/doi.org\/10.1002\/hep.26141\n                    \n                  .","journal-title":"Hepatology."},{"issue":"1","key":"299_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41\u201352. \n                    https:\/\/doi.org\/10.1056\/NEJM200107053450107\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"10049","key":"299_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388(10049):1081\u20138. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)30579-7\n                    \n                  .","journal-title":"Lancet."},{"issue":"6","key":"299_CR5","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.26218","volume":"57","author":"H Razavi","year":"2013","unstructured":"Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164\u201370. \n                    https:\/\/doi.org\/10.1002\/hep.26218\n                    \n                  .","journal-title":"Hepatology."},{"issue":"1","key":"299_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","volume":"48","author":"JI Esteban","year":"2008","unstructured":"Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48(1):148\u201362. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2007.07.033\n                    \n                  .","journal-title":"J Hepatol"},{"issue":"9791","key":"299_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571\u201383. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)61097-0\n                    \n                  .","journal-title":"Lancet."},{"key":"299_CR8","volume-title":"Cambodia country progress report: monitoring progress towards the 2011 UN political declaration on HIV and AIDS","author":"National AIDS Authority","year":"2015","unstructured":"National AIDS Authority. Cambodia country progress report: monitoring progress towards the 2011 UN political declaration on HIV and AIDS. Phnom Penh: National AIDS Authority; 2015."},{"key":"299_CR9","volume-title":"National Popualtion size estimation, HIV related risk behaviors, HIV prevalence among people who use drugs in Cambodia in 2012","author":"C Chhea","year":"2014","unstructured":"Chhea C, Heng S, Tuot S. National Popualtion size estimation, HIV related risk behaviors, HIV prevalence among people who use drugs in Cambodia in 2012. Phnom Penh: National Authority for Combating Drugs and KHANA; 2014."},{"key":"299_CR10","volume-title":"Standard operating procedures for HIV testing and counseling (HTC)","author":"National Center for HIV\/AIDS, Dermatology and STD","year":"2012","unstructured":"National Center for HIV\/AIDS, Dermatology and STD. Standard operating procedures for HIV testing and counseling (HTC). Phnom Penh: National Center for HIV\/AIDS, Dermatology and STD; 2012."},{"issue":"8","key":"299_CR11","doi-asserted-by":"publisher","first-page":"e0183530","DOI":"10.1371\/journal.pone.0183530","volume":"12","author":"A Weggheleire De","year":"2017","unstructured":"De Weggheleire A, An S, De Baetselier I, Soeung P, Keath H, So V, et al. A cross-sectional study of hepatitis C among people living with HIV in Cambodia: prevalence, risk factors, and potential for targeted screening. PLoS One. 2017;12(8):e0183530. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0183530\n                    \n                  .","journal-title":"PLoS One"},{"key":"299_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4172\/2155-6113.1000161","volume":"3","author":"N Lerolle","year":"2012","unstructured":"Lerolle N, Limsreng S, Fournier-Nicolle I, Ly S, Nouhin J, Guillard B, et al. High frequency of advanced hepatic disease among HIV\/HCV co-infected patients in Cambodia: the HEPACAM study (ANRS 12267). J AIDS Clinic Res. 2012;3:161. \n                    https:\/\/doi.org\/10.4172\/2155-6113.1000161\n                    \n                  .","journal-title":"J AIDS Clinic Res"},{"issue":"2","key":"299_CR13","doi-asserted-by":"publisher","first-page":"e88552","DOI":"10.1371\/journal.pone.0088552","volume":"9","author":"J Griensven van","year":"2014","unstructured":"van Griensven J, Phirum L, Choun K, Thai S, De Weggheleire A, Lynen L. Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia. PLoS One. 2014;9(2):e88552. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0088552\n                    \n                  .","journal-title":"PLoS One"},{"issue":"5","key":"299_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.drugpo.2007.04.004","volume":"18","author":"C Aceijas","year":"2007","unstructured":"Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352\u20138. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2007.04.004\n                    \n                  .","journal-title":"Int J Drug Policy."},{"issue":"20","key":"299_CR15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867\u201377. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1214854\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"13","key":"299_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195\u2013206. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1010494\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"299_CR17","volume-title":"Law on Control of Drugs","author":"United Nations High Commissioner for Human Rights","year":"1996","unstructured":"United Nations High Commissioner for Human Rights. Law on Control of Drugs. Phnom Penh: United Nations High Commissioner for Human Rights; 1996."},{"key":"299_CR18","volume-title":"HIV\/AIDS flagship annual progress report","author":"KHANA","year":"2017","unstructured":"KHANA. HIV\/AIDS flagship annual progress report. Phnom Penh: KHANA; 2017."},{"issue":"12","key":"299_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jclinepi.2015.04.002","volume":"68","author":"RG White","year":"2015","unstructured":"White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, et al. Strengthening the reporting of observational studies in epidemiology for respondent-driven sampling studies: \u201cSTROBE-RDS\u201d statement. J Clin Epidemiol. 2015;68(12):1463\u201371. \n                    https:\/\/doi.org\/10.1016\/j.jclinepi.2015.04.002\n                    \n                  .","journal-title":"J Clin Epidemiol"},{"key":"299_CR20","volume-title":"Prequalification of in vitro diagnostics: Oraquick HCV rapid antibody test kit. Public report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Prequalification of in vitro diagnostics: Oraquick HCV rapid antibody test kit. Public report. Geneva: World Health Organization; 2017."},{"key":"299_CR21","volume-title":"WHO information note on the use of dual HIV\/syphilis rapid diagnostic tests (RDT)","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. WHO information note on the use of dual HIV\/syphilis rapid diagnostic tests (RDT). Geneva: World Health Organization; 2018."},{"key":"299_CR22","volume-title":"HIV rapid diagnostic tests (detection of HIV-1\/2 antibodies)","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. HIV assays opreational characteristics. In: HIV rapid diagnostic tests (detection of HIV-1\/2 antibodies). Geneva: World Health Organization; 2013."},{"key":"299_CR23","volume-title":"Integrated biological and behavioral survey among transgender women in Cambodia","author":"P Mun","year":"2016","unstructured":"Mun P, Tuot S, Chhim S, Chhoun P, Ly C, Pal K, et al. Integrated biological and behavioral survey among transgender women in Cambodia. Phnom Penh: National Center for HIV\/AIDS, Dermatology and STD; 2016."},{"key":"299_CR24","volume-title":"The sustainable action against HIV and AIDS in communities (SAHACOM): end-of-project evaluation","author":"S Yi","year":"2014","unstructured":"Yi S, Chhoun P, Brant S, Kita K, Tuot S. The sustainable action against HIV and AIDS in communities (SAHACOM): end-of-project evaluation. Phnom Penh: KHANA; 2014."},{"key":"299_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drugpo.2016.06.002","volume":"36","author":"S Yi","year":"2016","unstructured":"Yi S, Tuot S, Chhoun P, Pal K, Choub SC, Mburu G. Prevalence and correlates of psychological distress among drug users in Phnom Penh, Cambodia. Int J Drug Policy. 2016;36:25\u201332. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2016.06.002\n                    \n                  .","journal-title":"Int J Drug Policy."},{"issue":"7","key":"299_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2105\/AJPH.2011.300398","volume":"102","author":"BA Bell","year":"2012","unstructured":"Bell BA, Onwuegbuzie AJ, Ferron JM, Jiao QG, Hibbard ST, Kromrey JD. Use of design effects and sample weights in complex health survey data: a review of published articles using data from 3 commonly used adolescent health surveys. Am J Public Health. 2012;102(7):1399\u2013405. \n                    https:\/\/doi.org\/10.2105\/AJPH.2011.300398\n                    \n                  .","journal-title":"Am J Public Health"},{"issue":"1","key":"299_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000318884","volume":"54","author":"S Akkarathamrongsin","year":"2011","unstructured":"Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, Tangkijvanich P, Poovorawan Y. Seroprevalence and genotype of hepatitis C virus among immigrant workers from Cambodia and Myanmar in Thailand. Intervirology. 2011;54(1):10\u20136. \n                    https:\/\/doi.org\/10.1159\/000318884\n                    \n                  .","journal-title":"Intervirology."},{"issue":"5","key":"299_CR28","first-page":"963","volume":"40","author":"HS Ol","year":"2009","unstructured":"Ol HS, Bjoerkvoll B, Sothy S, Van Heng Y, Hoel H, Husebekk A, et al. Prevalence of hepatitis B and hepatitis C virus infections in potential blood donors in rural Cambodia. Southeast Asian J Trop Med Public Health. 2009;40(5):963\u201371.","journal-title":"Southeast Asian J Trop Med Public Health."},{"issue":"2","key":"299_CR29","first-page":"239","volume":"24","author":"EG Thuring","year":"1993","unstructured":"Thuring EG, Joller-Jemelka HI, Sareth H, Sokhan U, Reth C, Grob P. Prevalence of markers of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. Southeast Asian J Trop Med Public Health. 1993;24(2):239\u201349.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"4","key":"299_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/hepr.12367","volume":"45","author":"H Yamada","year":"2015","unstructured":"Yamada H, Fujimoto M, Svay S, Lim O, Hok S, Goto N, et al. Seroprevalence, genotypic distribution and potential risk factors of hepatitis B and C virus infections among adults in Siem Reap, Cambodia. Hepatol Res. 2015;45(4):480\u20137. \n                    https:\/\/doi.org\/10.1111\/hepr.12367\n                    \n                  .","journal-title":"Hepatol Res"},{"issue":"5","key":"299_CR31","doi-asserted-by":"publisher","first-page":"e0177341","DOI":"10.1371\/journal.pone.0177341","volume":"12","author":"B Eckhardt","year":"2017","unstructured":"Eckhardt B, Winkelstein ER, Shu MA, Carden MR, McKnight C, Des Jarlais DC, et al. Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: implications for prevention. PLoS One. 2017;12(5):e0177341. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0177341\n                    \n                  .","journal-title":"PLoS One"},{"issue":"1","key":"299_CR32","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1186\/s12889-017-4933-0.","volume":"17","author":"A Khatib","year":"2017","unstructured":"Khatib A, Matiko E, Khalid F, Welty S, Ali A, Othman A, et al. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar. BMC Public Health. 2017;17(1):917. \n                    https:\/\/doi.org\/10.1186\/s12889-017-4933-0.","journal-title":"BMC Public Health"},{"issue":"6","key":"299_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3760\/cma.j.issn.0254-6450.2016.06.016.","volume":"37","author":"N Li","year":"2016","unstructured":"Li N, Wang XW, Nie YG, Ma YM, Yang WJ, Fan PY, et al. HCV infection status and related risk factors in drug users under HIV sentinel surveillance in Henan province, 2011-2015. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(6):821\u20135. \n                    https:\/\/doi.org\/10.3760\/cma.j.issn.0254-6450.2016.06.016.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"issue":"3","key":"299_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00705-017-3656-y","volume":"163","author":"FQ Silva","year":"2018","unstructured":"Silva FQ, Santos FJA, Andrade AP, Pacheco SDB, Fischer B, Pinho JRR, et al. Hepatitis C virus infection among illicit drug users in an archipelago of the Amazon. Arch Virol. 2018;163(3):617\u201322. \n                    https:\/\/doi.org\/10.1007\/s00705-017-3656-y\n                    \n                  .","journal-title":"Arch Virol"},{"issue":"1","key":"299_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/1753-6405.12741","volume":"42","author":"M Doyle","year":"2018","unstructured":"Doyle M, Maher L, Graham S, Wand H, Iversen J. Hepatitis C virus prevalence and associated risk factors among indigenous Australians who inject drugs. Aust N Z J Public Health. 2018;42(1):52\u20136. \n                    https:\/\/doi.org\/10.1111\/1753-6405.12741\n                    \n                  .","journal-title":"Aust N Z J Public Health"},{"issue":"10","key":"299_CR36","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1360-0443.2006.01543.x","volume":"101","author":"L Maher","year":"2006","unstructured":"Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101(10):1499\u2013508. \n                    https:\/\/doi.org\/10.1111\/j.1360-0443.2006.01543.x\n                    \n                  .","journal-title":"Addiction."},{"issue":"4","key":"299_CR37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jadohealth.2012.07.011","volume":"52","author":"C Feng","year":"2013","unstructured":"Feng C, DeBeck K, Kerr T, Mathias S, Montaner J, Wood E. Homelessness independently predicts injection drug use initiation among street-involved youth in a Canadian setting. J Adolesc Health. 2013;52(4):499\u2013501. \n                    https:\/\/doi.org\/10.1016\/j.jadohealth.2012.07.011\n                    \n                  .","journal-title":"J Adolesc Health"},{"issue":"4","key":"299_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/dar.12257","volume":"34","author":"E Whittaker","year":"2015","unstructured":"Whittaker E, Swift W, Roxburgh A, Dietze P, Cogger S, Bruno R, et al. Multiply disadvantaged: health and service utilisation factors faced by homeless injecting drug consumers in Australia. Drug Alcohol Rev. 2015;34(4):379\u201387. \n                    https:\/\/doi.org\/10.1111\/dar.12257\n                    \n                  .","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"299_CR39","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1017\/S0950268815002666","volume":"144","author":"YB Zhou","year":"2016","unstructured":"Zhou YB, Wang QX, Yang MX, Gong YH, Yang Y, Nie SJ, et al. Geographical variations of risk factors associated with HCV infection in drug users in southwestern China. Epidemiol Infect. 2016;144(6):1291\u2013300. \n                    https:\/\/doi.org\/10.1017\/S0950268815002666\n                    \n                  .","journal-title":"Epidemiol Infect"},{"issue":"1","key":"299_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drugpo.2013.05.019","volume":"25","author":"JJ Amon","year":"2014","unstructured":"Amon JJ, Pearshouse R, Cohen JE, Schleifer R. Compulsory drug detention in East and Southeast Asia: evolving government, UN and donor responses. Int J Drug Policy. 2014;25(1):13\u201320. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2013.05.019\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"299_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-015-0071-0","volume":"12","author":"P Tanguay","year":"2015","unstructured":"Tanguay P, Kamarulzaman A, Aramrattana A, Wodak A, Thomson N, Ali R, et al. Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. Harm Reduct J. 2015;12:31. \n                    https:\/\/doi.org\/10.1186\/s12954-015-0071-0\n                    \n                  .","journal-title":"Harm Reduct J"},{"issue":"7","key":"299_CR42","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1017\/S0950268814002040","volume":"143","author":"KJ Cullen","year":"2015","unstructured":"Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiol Infect. 2015;143(7):1398\u2013407. \n                    https:\/\/doi.org\/10.1017\/S0950268814002040\n                    \n                  .","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"299_CR43","first-page":"S131","volume":"3","author":"Z Nokhodian","year":"2012","unstructured":"Nokhodian Z, Meshkati M, Adibi P, Ataei B, Kassaian N, Yaran M, et al. Hepatitis C among intravenous drug users in Isfahan, Iran: a study of seroprevalence and risk factors. Int J Prev Med. 2012;3(Suppl 1):S131\u20138.","journal-title":"Int J Prev Med"},{"issue":"7","key":"299_CR44","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/cid\/ciw869","volume":"64","author":"MD Morris","year":"2017","unstructured":"Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, Prins M, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis. 2017;64(7):860\u20139. \n                    https:\/\/doi.org\/10.1093\/cid\/ciw869\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"6","key":"299_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5694\/mja13.00153","volume":"201","author":"B White","year":"2014","unstructured":"White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust. 2014;201(6):326\u20139.","journal-title":"Med J Aust"},{"issue":"7423","key":"299_CR46","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/bmj.327.7423.1075","volume":"327","author":"YJ Hutin","year":"2003","unstructured":"Hutin YJ, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ. 2003;327(7423):1075. \n                    https:\/\/doi.org\/10.1136\/bmj.327.7423.1075\n                    \n                  .","journal-title":"BMJ."},{"key":"299_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-5-56","volume":"5","author":"S Vong","year":"2005","unstructured":"Vong S, Perz JF, Sok S, Som S, Goldstein S, Hutin Y, et al. Rapid assessment of injection practices in Cambodia, 2002. BMC Public Health. 2005;5:56. \n                    https:\/\/doi.org\/10.1186\/1471-2458-5-56\n                    \n                  .","journal-title":"BMC Public Health"},{"issue":"3","key":"299_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","volume":"2","author":"N Islam","year":"2017","unstructured":"Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. Lancet Gastroenterol Hepatol. 2017;2(3):200\u201310. \n                    https:\/\/doi.org\/10.1016\/S2468-1253(16)30182-0\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"299_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(14)71045-X","volume":"15","author":"SS Solomon","year":"2015","unstructured":"Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis. 2015;15(1):36\u201345. \n                    https:\/\/doi.org\/10.1016\/S1473-3099(14)71045-X\n                    \n                  .","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"299_CR50","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2471\/BLT.11.097147","volume":"90","author":"N Ford","year":"2012","unstructured":"Ford N, Kirby C, Singh K, Mills EJ, Cooke G, Kamarulzaman A, et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ. 2012;90(7):540\u201350. \n                    https:\/\/doi.org\/10.2471\/BLT.11.097147\n                    \n                  .","journal-title":"Bull World Health Organ"},{"issue":"9916","key":"299_CR51","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515\u201323. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)62121-2\n                    \n                  .","journal-title":"Lancet."},{"issue":"3","key":"299_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1306218\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"12","key":"299_CR53","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/jvh.12969","volume":"25","author":"M Kaberg","year":"2018","unstructured":"Kaberg M, Naver G, Hammarberg A, Weiland O. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm needle exchange-importance for HCV elimination. J Viral Hepat. 2018;25(12):1452\u201361. \n                    https:\/\/doi.org\/10.1111\/jvh.12969\n                    \n                  .","journal-title":"J Viral Hepat"},{"issue":"4","key":"299_CR54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1360-0443.1993.tb02058.x","volume":"88","author":"CA Latkin","year":"1993","unstructured":"Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 1993;88(4):517\u201326.","journal-title":"Addiction."},{"key":"299_CR55","volume-title":"Guidelines on hepatitis B and C testing","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017."},{"issue":"Suppl 1","key":"299_CR56","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1186\/s12879-017-2773-2.","volume":"17","author":"W Tang","year":"2017","unstructured":"Tang W, Chen W, Amini A, Boeras D, Falconer J, Kelly H, et al. Diagnostic accuracy of tests to detect hepatitis C antibody: a meta-analysis and review of the literature. BMC Infect Dis. 2017;17(Suppl 1):695. \n                    https:\/\/doi.org\/10.1186\/s12879-017-2773-2.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"299_CR57","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.2105\/AJPH.2011.300251","volume":"101","author":"A Drobnik","year":"2011","unstructured":"Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101(11):2151\u20135. \n                    https:\/\/doi.org\/10.2105\/AJPH.2011.300251\n                    \n                  .","journal-title":"Am J Public Health"},{"issue":"12","key":"299_CR58","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207. \n                    https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3\n                    \n                  .","journal-title":"Lancet Glob Health"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0299-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T23:11:33Z","timestamp":1588029093000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0299-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0299-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SY (PhD) is Senior Research Fellow at Saw Swee Hock School of Public Health, National University of Singapore, Singapore and Director of KHANA Center for Population Health Research, Cambodia. ST (MA) is Manager and PC (MPH) is Research Fellow at KHANA Center for Population Health Research, Cambodia. PM (MPH) is Chief of Surveillance Unit and NC (MPH) is Deputy Chief of Surveillance Unit, National Center for HIV\/AIDS, Dermatology and STD. GM (MPH) is a Researcher at Division of Health Research, Lancaster University, the United Kingdom.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The National Ethics Committee for Health Research (NECHR) of the Ministry of Health, Cambodia approved the study\u00a0(No. 420 NECHR). A written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"29"}}